Aya Gold & Silver Inc. press release
ART to participate in FDA workshop on imaging technologies applied to drug development in Bethesda, Maryland
TSX - Toronto Stock Exchange · Silver · Gold · Zinc · Lead · Copper · Canada
Major FDA initiative in promoting the use of imaging in drug development and clinical response to therapy
MONTREAL, May 5 /CNW Telbec/ - ART Advanced Research Technologies Inc. ("ART") (TSX: ARA), a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, will be participating in break out sessions at an FDA workshop on the use of medical imaging as a drug development tool, being held in Bethesda, Maryland, from May 5 to 6, 2005. As part of the FDA's Critical Path Initiative, imaging technologies are considered to be at the forefront of efforts to apply new strategies and technologies streamlining the drug-approval process. "In this context, ART addresses a large unmet need within the pharmaceutical industry with its Time Domain (TD) optical imaging technology, using the power of optical molecular imaging to accelerate the delivery of better therapies and cures," said Micheline Bouchard, ART's President and CEO. Two products based on ART's technology platform - eXplore Optix and SoftScan - target two different but related markets: preclinical research and breast cancer diagnosis. These products have the potential to span the entire continuum of drug development: from the analysis of new compounds in laboratory animals, through to the diagnosis of disease and to the monitoring of a treatment's efficacy. SoftScan is intended to give the clinician new optical imaging tools for a better diagnosis of breast cancer and will grow to provide a platform for testing molecular imaging compounds in humans.
About ART
ART Advanced Research Technologies Inc. is a leader in optical molecular imaging products for the healthcare and pharmaceutical industries. ART has developed two products based on its innovative technology. The first is eXplore Optix(TM), a molecular imaging device designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs. eXplore Optix(TM) is distributed by GE Healthcare and is used by industry and academic leaders worldwide to bring new and better treatments to patients faster. The second is SoftScan(R), a medical imaging device designed to improve the diagnosis and treatment of breast cancer. ART is commercializing its products in a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. ART's shares are listed on the TSX under the ticker symbol ARA. Visit ART online at www.art.ca
This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in ART Advanced Research Technologies Inc.'s regulatory filings with Canadian Securities Commissions.